{"ast":null,"code":"var _jsxFileName = \"D:\\\\Downloads\\\\Explorer_V2\\\\src\\\\helpers\\\\cases.tsx\";\nimport React from 'react';\nexport const CASES = [{\n  disease: '10356.0',\n  drug: 'DB01612',\n  open_list: [1, 3],\n  description: /*#__PURE__*/React.createElement(\"span\", {\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 9,\n      columnNumber: 7\n    }\n  }, \"NSIAD is a rare genetic disorder of water and sodium imbalance that has prevalence of less than one in a million\", /*#__PURE__*/React.createElement(\"a\", {\n    href: \"https://www.orpha.net/\",\n    target: \"_blank\",\n    rel: \"noopener noreferrer\",\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 12,\n      columnNumber: 9\n    }\n  }, \"[Orphanet]\"), \". A mutation in the AVPR2 gene confirms diagnosis\", /*#__PURE__*/React.createElement(\"a\", {\n    href: \"https://www.orpha.net/\",\n    target: \"_blank\",\n    rel: \"noopener noreferrer\",\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 20,\n      columnNumber: 9\n    }\n  }, \"[Orphanet]\"), \". Patients with congestive heart failure also experience similar challenges with fluid retention. Congestive heart failure is strongly associated with both AVPR2 and NPR1 genes\", ' ', /*#__PURE__*/React.createElement(\"a\", {\n    href: \"https://www.orpha.net/\",\n    target: \"_blank\",\n    rel: \"noopener noreferrer\",\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 30,\n      columnNumber: 9\n    }\n  }, \"[Open targets]\"), \". The AVPR2 and NPR1 genes regulate fluid and electrolyte balance in the body through complementary but different pathways. While AVPR2 is involved in water retention and concentrating urine, NPR1 promotes vasodilation, decreased blood pressure, and increased excretion of water. Enhancing NPR1 activity could theoretically help counterbalance the excessive water reabsorption caused by the abnormally functioning AVPR2 receptors in NSIAD. The NPR1 gene is target for Amyl Nitrite, hence this drug could be a useful therapy in NSIAD patients\", /*#__PURE__*/React.createElement(\"a\", {\n    href: \"https://www.orpha.net/\",\n    target: \"_blank\",\n    rel: \"noopener noreferrer\",\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 45,\n      columnNumber: 9\n    }\n  }, \"[Drugbank]\"), \".\"),\n  paths: [['disease:10356.0', // nephrogenic syndrome of inappropriate antidiuresis\n  'gene/protein:554.0', // disease_protein -> AVPR2\n  'disease:5009.0', // disease_protein -> congestive heart failure\n  'gene/protein:4881.0', //disease_protein -> NPR1\n  'drug:DB01612' // drug_protein -> Amyl Nitrite\n  ]]\n}, {\n  disease: '19567_19568_7522',\n  drug: 'DB00755',\n  open_list: [1, 3],\n  description: /*#__PURE__*/React.createElement(\"span\", {\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 71,\n      columnNumber: 7\n    }\n  }, \"Ehlers-Danlos syndrome is a rare inherited connective tissue disorder caused by mutations in genes that code for collagen (such as COL1A1, COL1A2) with a prevalence of 1-9 / 100 000\", /*#__PURE__*/React.createElement(\"a\", {\n    href: \"https://www.orpha.net/\",\n    target: \"_blank\",\n    rel: \"noopener noreferrer\",\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 75,\n      columnNumber: 9\n    }\n  }, \"[Orphanet]\"), \". Key symptoms include impaired wound healing and formation of form atypical scars on the skin. Tretnoin is a vitamin A derivative used to treat acne and is carrier by albumin (ALB) and targets ALDH1A1 to prevents collagen loss and reduce inflammation\", /*#__PURE__*/React.createElement(\"a\", {\n    href: \"https://www.orpha.net/\",\n    target: \"_blank\",\n    rel: \"noopener noreferrer\",\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 86,\n      columnNumber: 9\n    }\n  }, \"[Drugbank]\"), \". Tretinoin may help in Ehlers-Danlos Syndrome by potentially enhancing wound healing and improving the appearance of scars due to its ability to stimulate collagen production in the skin. Some subtypes of Elhers-Danlos Syndrome are associated with a pathogenic mutation in the ALB gene in ClinVar and weakly linked to ALDH1AI in Europe PMC\", /*#__PURE__*/React.createElement(\"a\", {\n    href: \"https://www.orpha.net/\",\n    target: \"_blank\",\n    rel: \"noopener noreferrer\",\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 98,\n      columnNumber: 9\n    }\n  }, \"[Opentargets]\")),\n  paths: []\n}, {\n  disease: '27407_54701_12455',\n  drug: 'DB00425',\n  open_list: [0, 3],\n  description: /*#__PURE__*/React.createElement(\"span\", {\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 114,\n      columnNumber: 7\n    }\n  }, \"Kleefstra syndrome is a rare genetic, intellectual disability syndrome caused by mutations in EHMT1 characterized by little speech development, autism spectrum disorder, and childhood hypotonia with a prevalence of less than one in a million\", /*#__PURE__*/React.createElement(\"a\", {\n    href: \"https://www.orpha.net/\",\n    target: \"_blank\",\n    rel: \"noopener noreferrer\",\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 119,\n      columnNumber: 9\n    }\n  }, \"[Orphanet]\"), \". Zolpidem, commonly known as a sedative-hypnotic medication used for the short-term treatment of insomnia, has been found in some cases to have unexpected neurological benefits in various neurodevelopmental and neurodegenerative disorders. In neurodevelopmental disorders (such as Kleefstra syndrome), the brain might have dormant or underactive neurons due to genetic or molecular abnormalities. Zolpidem has been observed in some cases to temporarily \\u201Cawaken\\u201D these underactive neural pathways\", /*#__PURE__*/React.createElement(\"a\", {\n    href: \"https://www.orpha.net/\",\n    target: \"_blank\",\n    rel: \"noopener noreferrer\",\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 133,\n      columnNumber: 9\n    }\n  }, \"[study]\"), \". This effect is thought to be due to zolpidem\\u2019s action on GABA-A receptors (gene GABRG2) in the brain\", /*#__PURE__*/React.createElement(\"a\", {\n    href: \"https://www.orpha.net/\",\n    target: \"_blank\",\n    rel: \"noopener noreferrer\",\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 142,\n      columnNumber: 9\n    }\n  }, \"[Drugbank]\"), \". GABA-A receptors are inhibitory, meaning they reduce neuronal activity. Zolpidem typically enhances the inhibitory effects of GABA, leading to sedation. However, in certain neurological conditions, it may paradoxically improve neuronal activity in some brain regions [Case report]. There have been anecdotal reports and a few small studies suggesting that zolpidem may improve symptoms like speech, motor abilities, and alertness in some patients with severe brain injuries or neurodevelopmental disorders\", ' ', /*#__PURE__*/React.createElement(\"a\", {\n    href: \"https://www.orpha.net/\",\n    target: \"_blank\",\n    rel: \"noopener noreferrer\",\n    __self: this,\n    __source: {\n      fileName: _jsxFileName,\n      lineNumber: 157,\n      columnNumber: 9\n    }\n  }, \"[another study]\"), \".\"),\n  paths: [['disease:27407_54701_12455', // Kleefstra syndrome\n  'gene/protein:79813.0', // disease_protein -> EHMT1\n  'anatomy:7105.0', // anatomy_protein_present -> dorsolateral prefrontal cortex\n  'gene/protein:2554.0', // anatomy_protein_present -> GABRA1\n  'drug:DB00425' // -> drug_protein -> Zolpidemm\n  ]]\n}];","map":{"version":3,"sources":["D:/Downloads/Explorer_V2/src/helpers/cases.tsx"],"names":["React","CASES","disease","drug","open_list","description","paths"],"mappings":";AAAA,OAAOA,KAAP,MAAkB,OAAlB;AAEA,OAAO,MAAMC,KAAK,GAAG,CACnB;AACEC,EAAAA,OAAO,EAAE,SADX;AAEEC,EAAAA,IAAI,EAAE,SAFR;AAGEC,EAAAA,SAAS,EAAE,CAAC,CAAD,EAAI,CAAJ,CAHb;AAIEC,EAAAA,WAAW,eACT;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,sIAGE;AACE,IAAA,IAAI,EAAC,wBADP;AAEE,IAAA,MAAM,EAAC,QAFT;AAGE,IAAA,GAAG,EAAC,qBAHN;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,kBAHF,oEAWE;AACE,IAAA,IAAI,EAAC,wBADP;AAEE,IAAA,MAAM,EAAC,QAFT;AAGE,IAAA,GAAG,EAAC,qBAHN;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,kBAXF,sLAoB4C,GApB5C,eAqBE;AACE,IAAA,IAAI,EAAC,wBADP;AAEE,IAAA,MAAM,EAAC,QAFT;AAGE,IAAA,GAAG,EAAC,qBAHN;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,sBArBF,gjBAoCE;AACE,IAAA,IAAI,EAAC,wBADP;AAEE,IAAA,MAAM,EAAC,QAFT;AAGE,IAAA,GAAG,EAAC,qBAHN;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,kBApCF,MALJ;AAmDEC,EAAAA,KAAK,EAAE,CACL,CACE,iBADF,EACqB;AACnB,sBAFF,EAEwB;AACtB,kBAHF,EAGoB;AAClB,uBAJF,EAIyB;AACvB,gBALF,CAKkB;AALlB,GADK;AAnDT,CADmB,EA+DnB;AACEJ,EAAAA,OAAO,EAAE,kBADX;AAEEC,EAAAA,IAAI,EAAE,SAFR;AAGEC,EAAAA,SAAS,EAAE,CAAC,CAAD,EAAI,CAAJ,CAHb;AAIEC,EAAAA,WAAW,eACT;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,2MAIE;AACE,IAAA,IAAI,EAAC,wBADP;AAEE,IAAA,MAAM,EAAC,QAFT;AAGE,IAAA,GAAG,EAAC,qBAHN;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,kBAJF,8QAeE;AACE,IAAA,IAAI,EAAC,wBADP;AAEE,IAAA,MAAM,EAAC,QAFT;AAGE,IAAA,GAAG,EAAC,qBAHN;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,kBAfF,uWA2BE;AACE,IAAA,IAAI,EAAC,wBADP;AAEE,IAAA,MAAM,EAAC,QAFT;AAGE,IAAA,GAAG,EAAC,qBAHN;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,qBA3BF,CALJ;AAyCEC,EAAAA,KAAK,EAAE;AAzCT,CA/DmB,EA0GnB;AACEJ,EAAAA,OAAO,EAAE,mBADX;AAEEC,EAAAA,IAAI,EAAE,SAFR;AAGEC,EAAAA,SAAS,EAAE,CAAC,CAAD,EAAI,CAAJ,CAHb;AAIEC,EAAAA,WAAW,eACT;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,uQAKE;AACE,IAAA,IAAI,EAAC,wBADP;AAEE,IAAA,MAAM,EAAC,QAFT;AAGE,IAAA,GAAG,EAAC,qBAHN;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,kBALF,6gBAmBE;AACE,IAAA,IAAI,EAAC,wBADP;AAEE,IAAA,MAAM,EAAC,QAFT;AAGE,IAAA,GAAG,EAAC,qBAHN;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,eAnBF,8HA4BE;AACE,IAAA,IAAI,EAAC,wBADP;AAEE,IAAA,MAAM,EAAC,QAFT;AAGE,IAAA,GAAG,EAAC,qBAHN;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,kBA5BF,igBA0C+B,GA1C/B,eA2CE;AACE,IAAA,IAAI,EAAC,wBADP;AAEE,IAAA,MAAM,EAAC,QAFT;AAGE,IAAA,GAAG,EAAC,qBAHN;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA;AAAA,uBA3CF,MALJ;AA0DEC,EAAAA,KAAK,EAAE,CACL,CACE,2BADF,EAC+B;AAC7B,wBAFF,EAE0B;AACxB,kBAHF,EAGoB;AAClB,uBAJF,EAIyB;AACvB,gBALF,CAKkB;AALlB,GADK;AA1DT,CA1GmB,CAAd","sourcesContent":["import React from 'react';\n\nexport const CASES = [\n  {\n    disease: '10356.0',\n    drug: 'DB01612',\n    open_list: [1, 3],\n    description: (\n      <span>\n        NSIAD is a rare genetic disorder of water and sodium imbalance that has\n        prevalence of less than one in a million\n        <a\n          href=\"https://www.orpha.net/\"\n          target=\"_blank\"\n          rel=\"noopener noreferrer\"\n        >\n          [Orphanet]\n        </a>\n        . A mutation in the AVPR2 gene confirms diagnosis\n        <a\n          href=\"https://www.orpha.net/\"\n          target=\"_blank\"\n          rel=\"noopener noreferrer\"\n        >\n          [Orphanet]\n        </a>\n        . Patients with congestive heart failure also experience similar\n        challenges with fluid retention. Congestive heart failure is strongly\n        associated with both AVPR2 and NPR1 genes{' '}\n        <a\n          href=\"https://www.orpha.net/\"\n          target=\"_blank\"\n          rel=\"noopener noreferrer\"\n        >\n          [Open targets]\n        </a>\n        . The AVPR2 and NPR1 genes regulate fluid and electrolyte balance in the\n        body through complementary but different pathways. While AVPR2 is\n        involved in water retention and concentrating urine, NPR1 promotes\n        vasodilation, decreased blood pressure, and increased excretion of\n        water. Enhancing NPR1 activity could theoretically help counterbalance\n        the excessive water reabsorption caused by the abnormally functioning\n        AVPR2 receptors in NSIAD. The NPR1 gene is target for Amyl Nitrite,\n        hence this drug could be a useful therapy in NSIAD patients\n        <a\n          href=\"https://www.orpha.net/\"\n          target=\"_blank\"\n          rel=\"noopener noreferrer\"\n        >\n          [Drugbank]\n        </a>\n        .\n      </span>\n    ),\n    paths: [\n      [\n        'disease:10356.0', // nephrogenic syndrome of inappropriate antidiuresis\n        'gene/protein:554.0', // disease_protein -> AVPR2\n        'disease:5009.0', // disease_protein -> congestive heart failure\n        'gene/protein:4881.0', //disease_protein -> NPR1\n        'drug:DB01612', // drug_protein -> Amyl Nitrite\n      ],\n    ],\n  },\n\n  {\n    disease: '19567_19568_7522',\n    drug: 'DB00755',\n    open_list: [1, 3],\n    description: (\n      <span>\n        Ehlers-Danlos syndrome is a rare inherited connective tissue disorder\n        caused by mutations in genes that code for collagen (such as COL1A1,\n        COL1A2) with a prevalence of 1-9 / 100 000\n        <a\n          href=\"https://www.orpha.net/\"\n          target=\"_blank\"\n          rel=\"noopener noreferrer\"\n        >\n          [Orphanet]\n        </a>\n        . Key symptoms include impaired wound healing and formation of form\n        atypical scars on the skin. Tretnoin is a vitamin A derivative used to\n        treat acne and is carrier by albumin (ALB) and targets ALDH1A1 to\n        prevents collagen loss and reduce inflammation\n        <a\n          href=\"https://www.orpha.net/\"\n          target=\"_blank\"\n          rel=\"noopener noreferrer\"\n        >\n          [Drugbank]\n        </a>\n        . Tretinoin may help in Ehlers-Danlos Syndrome by potentially enhancing\n        wound healing and improving the appearance of scars due to its ability\n        to stimulate collagen production in the skin. Some subtypes of\n        Elhers-Danlos Syndrome are associated with a pathogenic mutation in the\n        ALB gene in ClinVar and weakly linked to ALDH1AI in Europe PMC\n        <a\n          href=\"https://www.orpha.net/\"\n          target=\"_blank\"\n          rel=\"noopener noreferrer\"\n        >\n          [Opentargets]\n        </a>\n      </span>\n    ),\n    paths: [],\n  },\n  {\n    disease: '27407_54701_12455',\n    drug: 'DB00425',\n    open_list: [0, 3],\n    description: (\n      <span>\n        Kleefstra syndrome is a rare genetic, intellectual disability syndrome\n        caused by mutations in EHMT1 characterized by little speech development,\n        autism spectrum disorder, and childhood hypotonia with a prevalence of\n        less than one in a million\n        <a\n          href=\"https://www.orpha.net/\"\n          target=\"_blank\"\n          rel=\"noopener noreferrer\"\n        >\n          [Orphanet]\n        </a>\n        . Zolpidem, commonly known as a sedative-hypnotic medication used for\n        the short-term treatment of insomnia, has been found in some cases to\n        have unexpected neurological benefits in various neurodevelopmental and\n        neurodegenerative disorders. In neurodevelopmental disorders (such as\n        Kleefstra syndrome), the brain might have dormant or underactive neurons\n        due to genetic or molecular abnormalities. Zolpidem has been observed in\n        some cases to temporarily “awaken” these underactive neural pathways\n        <a\n          href=\"https://www.orpha.net/\"\n          target=\"_blank\"\n          rel=\"noopener noreferrer\"\n        >\n          [study]\n        </a>\n        . This effect is thought to be due to zolpidem’s action on GABA-A\n        receptors (gene GABRG2) in the brain\n        <a\n          href=\"https://www.orpha.net/\"\n          target=\"_blank\"\n          rel=\"noopener noreferrer\"\n        >\n          [Drugbank]\n        </a>\n        . GABA-A receptors are inhibitory, meaning they reduce neuronal\n        activity. Zolpidem typically enhances the inhibitory effects of GABA,\n        leading to sedation. However, in certain neurological conditions, it may\n        paradoxically improve neuronal activity in some brain regions [Case\n        report]. There have been anecdotal reports and a few small studies\n        suggesting that zolpidem may improve symptoms like speech, motor\n        abilities, and alertness in some patients with severe brain injuries or\n        neurodevelopmental disorders{' '}\n        <a\n          href=\"https://www.orpha.net/\"\n          target=\"_blank\"\n          rel=\"noopener noreferrer\"\n        >\n          [another study]\n        </a>\n        .\n      </span>\n    ),\n    paths: [\n      [\n        'disease:27407_54701_12455', // Kleefstra syndrome\n        'gene/protein:79813.0', // disease_protein -> EHMT1\n        'anatomy:7105.0', // anatomy_protein_present -> dorsolateral prefrontal cortex\n        'gene/protein:2554.0', // anatomy_protein_present -> GABRA1\n        'drug:DB00425', // -> drug_protein -> Zolpidemm\n      ],\n    ],\n  },\n];\n"]},"metadata":{},"sourceType":"module"}